Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: quidditch who wrote (5426)	1/14/2002 10:29:03 AM
From: Biomaven	Respond to of 52153

quid, There's an automatic 30 month stay as soon as KOSP files suit against the would be generic. Thus I couldn't see any competitor being on the market much before 2005 even assuming the unknown generic company was to win the patent dispute. Note there are some pretty strong patents on the list where there has been a Para. IV filing - e.g., Allegra. The KOSP patents are somewhat murky, but KOSP are helped some by the fact that other niacin time-releases have liver tox issues. Thus the FDA might be reluctant to allow a competitor that isn't an exact duplicate to get on the market without trials. I continue to maintain a reduced position. Peter